Image de couverture de livre

Selective JAK1 inhibition with abrocitinib in refractory disseminated granuloma annulare: A descriptive real‐world case series

Fuente: Wiley Open Access

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Gaetano Licata, Anna Balato, Paolino Franzese, Pasquale Sorrentino, Giuseppe Argenziano, Caterina Mariarosaria Giorgio
Format:	Artículo Open Access
Publié:	Wiley 2026
Sujets:	JDDG: Journal der Deutschen Dermatologischen Gesellschaft
Accès en ligne:	Acceder al recurso
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Successful treatment of recalcitrant generalized granuloma annulare with the JAK inhibitor abrocitinib
par: Alexander Michels, et autres
Publié: (2024)

Topical propranolol and sirolimus in Pentravan: A promising non‐systemic approach for Kaposi's sarcoma management
par: Caterina Mariarosaria Giorgio, et autres
Publié: (2025)

What about this solitary skin lesion? Clinical, dermatoscopy and histological findings with differential diagnoses
par: Vittorio Tancredi, et autres
Publié: (2024)

A case of successful treatment of nail psoriasis with abrocitinib
par: Teng Liu, et autres
Publié: (2025)

Histology and line‐field confocal optical coherence tomography in granuloma faciale: A single case study
par: Cesare Ariasi, et autres
Publié: (2024)

Real‐world use of anifrolumab in refractory cutaneous lupus: case series and review of the literature
par: Victoria Martínez‐Sernández, et autres
Publié: (2026)

Severe and disseminated atypical mycobacteriosis of the skin under immunosuppression
par: Veronika Zenderowski, et autres
Publié: (2026)

Überbrückung der therapeutischen Versorgungslücke mit JAK‐Inhibitoren
par: Diamant Thaçi
Publié: (2025)

Bridging the Therapeutic Unmet Need Gap with JAK Inhibitors
par: Diamant Thaçi
Publié: (2025)

Acyclovir‐unresponsive disseminated herpes zoster in B‐cell chronic lymphocytic leukemia
par: Tabael L. Turan, et autres
Publié: (2025)

Granuloma annulare following SARS‐CoV‐2 infection: a new case and review of the literature
par: Biagio Scotti, et autres
Publié: (2025)

Severe mixed hand and generalized eczema treated with the JAK inhibitor upadacitinib
par: Neda Cramer, et autres
Publié: (2024)

Long‐term disease control of disseminated superficial actinic porokeratosis (DSAP) with simvastatin 2%/ cholesterol 2% cream
par: Berenice M. Lang, et autres
Publié: (2025)

Erfolgreiche Behandlung eines therapieresistenten generalisierten Granuloma anulare mit dem JAK‐Inhibitor Abrocitinib
par: Alexander Michels, et autres
Publié: (2024)

Therapie eines schweren gemischten Handekzems und generalisierten Ekzems mit dem JAK‐Inhibitor Upadacitinib
par: Neda Cramer, et autres
Publié: (2025)

Atopic dermatitis relapse after treatment discontinuation and predictive factors for relapse: JAK1 inhibitors versus dupilumab
par: Hanwen Wu, et autres
Publié: (2025)

Aseptic meningitis due to intravenous immunoglobulin therapy (IVIG) in therapy‐refractory pyoderma gangraenosum
par: Katharina A. Kälber, et autres
Publié: (2026)

Adjuvant therapy of severe and/or refractory bullous pemphigoid with immunoadsorption – A prospective monocenter pilot study
par: Maike M. Holtsche, et autres
Publié: (2025)

Chronic rhinosinusitis during immune checkpoint inhibition in melanoma patients
par: Yenny Angela, et autres
Publié: (2026)

Treatment of reactive perforating collagenosis with two forms of phosphodiesterase 4 inhibition
par: Sabrina Schundler, et autres
Publié: (2025)

Interleukin‐13 inhibition and cancer risk: A Mendelian randomization study
par: Zhenwei Tang, et autres
Publié: (2025)

Real‐world effectiveness and safety of the LAight‐therapy in patients with hidradenitis suppurativa
par: Alexandra Strobel, et autres
Publié: (2024)

I. Act with purpose, lead with your heart, make a positive impact on the world
Publié: (2026)

Real‐world experience with upadacitinib in hidradenitis suppurativa: efficacy and safety in patients with dermatological comorbidities
par: Alessandra Michelucci, et autres
Publié: (2026)

„Reverse underwear sign“ als Indikator für Alloknesis
par: Jie Zhu, et autres
Publié: (2024)

Reverse underwear sign as an indicator of alloknesis
par: Jie Zhu, et autres
Publié: (2024)

Real‐world management bei Patienten mit Komplettremission unter Immuncheckpoint‐Inhibition bei fortgeschrittenem Melanom
par: Markus Reitmajer, et autres
Publié: (2025)

Expertise in dermatologic emergencies: real‐world study on in‐person vs. teledermatology emergencies in a reference center
par: Charbel Skayem, et autres
Publié: (2024)

Real‐world evidence of tirbanibulin in the treatment of actinic keratosis in Germany – prospective, multicenter, non‐interventional KLIR study
par: Markus V. Heppt, et autres
Publié: (2025)

Histologie und Line‐Field konfokale optische Kohärenztomographie bei Granuloma faciale: Eine Kasuistik
par: Cesare Ariasi, et autres
Publié: (2024)

IL‐17 and IL‐23 inhibitors dose spacing in adult psoriatic patients: a real‐world pilot study
par: Luca Mastorino, et autres
Publié: (2025)

Real‐world management of adjuvant systemic melanoma therapy: Multi‐center survey of 51 DeCOG skin cancer centers
par: Markus Reitmajer, et autres
Publié: (2025)

Drug survival und klinische Wirksamkeit von Secukinumab, Ixekizumab, Brodalumab, Guselkumab, Risankizumab und Tildrakizumab in der Behandlung der Psoriasis
par: Luca Mastorino, et autres
Publié: (2024)

Pyoderma gangrenosum and spider bites: a case series
par: Luca Rapparini, et autres
Publié: (2025)

Complications of Laser and Energy‐Based Procedures in Dermatology: Classification, Management, and Prevention
par: Lynhda Nguyen, et autres
Publié: (2026)

Alternating ablative fractional laser and microneedling radiofrequency outperforms ablative fractional laser alone for acne scars
par: Haoyu He, et autres
Publié: (2025)

VIII. Innovation in lymphedema surgery
Publié: (2026)

X. Visualisierung und Beurteilung als Basis wissenschaftlicher Arbeit
Publié: (2026)

Autorenindex – Abstractnummern (Nr.)
Publié: (2026)

VI. Das Lymphödem im Hals‐, Kopf‐ und Gesichtsbereich
Publié: (2026)